share_log

華領醫藥-B:致登記股東之通知信函及回條

HUA MEDICINE-B: NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM

HKEX ·  Sep 26 16:38

Summary by Moomoo AI

華領醫藥於2024年9月26日發出通知,告知股東中期報告2024已可在公司及香港聯合交易所有限公司網站上獲得。公司鼓勵股東透過網站閱讀該報告及未來所有公司通訊。若股東希望收到印刷版的公司通訊,可填寫回條並透過郵件或電郵方式回傳給卓佳證券登記有限公司。公司亦提醒股東更新有效的電子郵件地址,以便透過電子郵件接收公司通訊。股東如有疑問,可於工作日致電卓佳證券登記有限公司熱線查詢。
華領醫藥於2024年9月26日發出通知,告知股東中期報告2024已可在公司及香港聯合交易所有限公司網站上獲得。公司鼓勵股東透過網站閱讀該報告及未來所有公司通訊。若股東希望收到印刷版的公司通訊,可填寫回條並透過郵件或電郵方式回傳給卓佳證券登記有限公司。公司亦提醒股東更新有效的電子郵件地址,以便透過電子郵件接收公司通訊。股東如有疑問,可於工作日致電卓佳證券登記有限公司熱線查詢。
HuaLing Pharmaceuticals issued a notice on September 26, 2024, informing shareholders that the interim report for 2024 can now be obtained on the company's website and the Hong Kong Stock Exchange website. The company encourages shareholders to read the report and all future company communications through the website. If shareholders wish to receive a printed version of the company's communications, they can fill out the reply form and return it to ZUOJIA Securities Registration Limited by mail or email. The company also reminds shareholders to update their valid email addresses to receive company communications via email. Shareholders with any questions can call the ZUOJIA Securities Registration Limited hotline on weekdays.
HuaLing Pharmaceuticals issued a notice on September 26, 2024, informing shareholders that the interim report for 2024 can now be obtained on the company's website and the Hong Kong Stock Exchange website. The company encourages shareholders to read the report and all future company communications through the website. If shareholders wish to receive a printed version of the company's communications, they can fill out the reply form and return it to ZUOJIA Securities Registration Limited by mail or email. The company also reminds shareholders to update their valid email addresses to receive company communications via email. Shareholders with any questions can call the ZUOJIA Securities Registration Limited hotline on weekdays.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more